Supplementary Figure 6.

IL6 protects from DSS-induced colitis. (A) Scheme of IL6 or vehicle administration during colitis induction, on day 10 mice were starved for 4 hours before oral FITC-dextran administration. (B and C) Histological assessment of (B) number of ulcers and (C) inflammation scores on colon sections of mice supplemented with IL6 during DSS treatment. Data are mean ± SEM. ***P < .001, t test. (D) BrdU IF stainings, arrowheads depict BrdU⁺ IECs. (E) IF double staining for pSTAT3 and CD64. Arrowheads depict presence of pSTAT3⁺/CD64⁺ cells. (F) Scheme of anti-IL6 or isotype control antibody administration during colitis induction, on day 10 mice were starved for 4 hours before oral FITC-dextran administration. (G and H) Histological assessment of number of ulcers (G) and inflammation scores (H) on colon sections of IL6-depleted mice (n ≥6). Data are mean ± SEM. (I) BrdU IF staining, arrowheads depict BrdU⁺ IECs. Scale bars 50 μm.